Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study

Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study

The three approved cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including abemaciclib, have shown differences in their preclinical, pharmacological, and clinical data. Abemaciclib stands out for its broader target range and more rapid and intense activity. It has demonstrated efficacy as a monot...

Full description

Bibliographic Details
Main Authors: Alicia Milagros de Luna Aguilar, Javier David Benitez Fuentes, Justo Ortega Anselmi, Jennifer Olalla Inoa, Paloma Flores Navarro, Alfonso Lopez de Sá, Jesus Fuentes Antras, Cristina Rodríguez Rey, Aída Ortega Candil, Fernando Moreno Antón, Jose Ángel García Sáenz
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Cancers
Subjects:
metastatic breast cancer
continuing CDK4/6 inhibition
abemaciclib
endocrine therapy
rechallenge
Online Access:https://www.mdpi.com/2072-6694/15/18/4452

Similar Items

Similar Items